Data protection Impressum

Biotech

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2024)

30 April 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

The FIF has once again highlighted its commitment to propelling tech innovation in Geneva by awarding significant financial support to three promising projects.

Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support

29 April 2024

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: reliable partners beyond borders

23 April 2024

Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding to advance its revolutionary diagnostic technologies.

Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding

22 April 2024

This initiative reflects a broader shift towards life sciences, driven by innovation and a commitment to health, wellness, and sustainability.

The HES-SO strengthens life sciences education and research in the canton of Valais

22 April 2024

Vaud-based biopharma Oculis has secured USD 59 million to extend operations into 2026, following a successful listing on NASDAQ Iceland Main Market.

Oculis announces completion of oversubscribed USD 59 million registered direct offering

15 April 2024

Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug development.

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment

9 April 2024

1 … 7 8 9 10 11 12 13 14 15 … 24